An Act to amend and reenact §§ 38.2-3407.15:2, as it is currently effective and as it shall become effective, and 38.2-3407.15:8 of the Code of Virginia, relating to prior authorization; requiring physician review for denial.
HB 481 amends Virginia insurance law governing prior authorization for prescription drugs. The bill requires carrier contracts with participating prescribers to accept prior authorization requests electronically, telephonically, or by fax from approved electronic prescribing and health information systems, and it sets specific response deadlines for urgent and routine requests. Carriers must respond to urgent requests within 24 hours and to completed routine requests within two business days, either approving, denying, or requesting supplementation. The bill also requires carriers to provide denial reasons within the same timeframes and to maintain a tracking system for all prior authorization requests.
The bill further limits when an approved prior authorization may be revoked or modified after a drug has been scheduled, provided, or delivered, generally allowing changes only in narrow circumstances such as fraud, FDA or manufacturer action, drug interaction concerns, or the addition of a generic or biosimilar. It also requires new carriers to honor a prior carrier’s approval for at least the first 90 days of a member’s new prescription drug coverage, subject to the new plan’s terms and certain exceptions. In addition, the bill preserves that carriers are not required to cover benefits not otherwise covered or to cover drugs after coverage has ended.
HB 481 amends §§ 38.2-3407.15:2 and 38.2-3407.15:8 of the Code of Virginia, tightening statutory requirements for health insurers and other carriers that use prior authorization for prescription drugs. It imposes procedural duties on carriers, expands the required methods of submission and communication, and creates continuity protections for patients changing health plans. The bill affects carriers, prescribers, pharmacies, and insured patients by speeding decisions, requiring clearer denial explanations, and reducing disruption when coverage changes.
The bill appears generally favorable and consumer-oriented, reflecting a policy preference for faster, more transparent prior authorization decisions and less administrative burden on prescribers and patients. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of debate or opposition in the supplied materials. The enacted chapter status suggests the measure ultimately received sufficient support to pass and become law.
The main policy tensions inherent in the bill are between patient access and insurer utilization management. Supporters would likely emphasize timely access to medications, continuity of care, and reduced administrative delays, while carriers may be concerned about reduced flexibility to revisit approvals, added administrative requirements, and limits on post-approval changes. The bill’s exceptions for fraud, safety issues, drug interactions, and formulary changes indicate an attempt to balance those concerns, but the most likely point of contention is whether the new deadlines and mandatory honoring of prior approvals unduly constrain carrier oversight.